{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:18:34Z","timestamp":1794406714004,"version":"4.9.0"},"reference-count":219,"publisher":"Bentham Science Publishers Ltd.","issue":"5","funder":[{"name":"\"Wellcome Clinical Postdoctoral Training Fellowship\"","award":["WT104422MA"],"award-info":[{"award-number":["WT104422MA"]}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Foundation","doi-asserted-by":"publisher","award":["166204"],"award-info":[{"award-number":["166204"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Unitaid","award":["2016-08-UoL"],"award-info":[{"award-number":["2016-08-UoL"]}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2019,6,3]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Remarkable progress has been achieved in the identification of HIV infection in pregnant women and in the prevention of vertical HIV transmission through maternal antiretroviral treatment (ART) and neonatal antiretroviral drug (ARV) prophylaxis in the last two decades. Millions of women globally are receiving combination ART throughout pregnancy and breastfeeding, periods associated with significant biological and physiological changes affecting the pharmacokinetics (PK) and pharmacodynamics (PD) of ARVs. The objective of this review was to summarize currently available knowledge on the PK of ARVs during pregnancy and transport of maternal ARVs through the placenta and into the breast milk. We also summarized main safety considerations for in utero and breast milk ARVs exposures in infants.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>We conducted a review of the pharmacological profiles of ARVs in pregnancy and during breastfeeding obtained from published clinical studies. Selected maternal PK studies used a relatively rich sampling approach at each ante- and postnatal sampling time point. For placental and breast milk transport of ARVs, we selected the studies that provided ratios of maternal to the cord (M:C) plasma and breast milk to maternal plasma (M:P) concentrations, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>We provide an overview of the physiological changes during pregnancy and their effect on the PK parameters of ARVs by drug class in pregnancy, which were gathered from 45 published studies. The PK changes during pregnancy affect the dosing of several protease inhibitors during pregnancy and limit the use of several ARVs, including three single tablet regimens with integrase inhibitors or protease inhibitors co-formulated with cobicistat due to suboptimal exposures. We further analysed the currently available data on the mechanism of the transport of ARVs from maternal plasma across the placenta and into the breast milk and summarized the effect of pregnancy on placental and of breastfeeding on mammal gland drug transporters, as well as physicochemical properties, C:M and M:P ratios of individual ARVs by drug class. Finally, we discussed the major safety issues of fetal and infant exposure to maternal ARVs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>Available pharmacological data provide evidence that physiological changes during pregnancy affect maternal, and consequently, fetal ARV exposure. Limited available data suggest that the expression of drug transporters may vary throughout pregnancy and breastfeeding thereby possibly impacting the amount of ARV crossing the placenta and secreted into the breast milk. The drug transporter\u2019s role in the fetal\/child exposure to maternal ARVs needs to be better understood. Our analysis underscores the need for more pharmacological studies with innovative study design, sparse PK sampling, improved study data reporting and PK modelling in pregnant and breastfeeding women living with HIV to optimize their treatment choices and maternal and child health outcomes.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1381612825666190320162507","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T07:32:56Z","timestamp":1553153576000},"page":"556-576","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Pharmacokinetics, Placental and Breast Milk Transfer of Antiretroviral Drugs in Pregnant and Lactating Women Living with HIV"],"prefix":"10.2174","volume":"25","author":[{"given":"E.M.","family":"Hodel","sequence":"first","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology, University of Liverpool, Molecular & Clinical Pharmacology, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Marzolini","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology, University of Liverpool, Molecular & Clinical Pharmacology, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Waitt","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology, University of Liverpool, Molecular & Clinical Pharmacology, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Rakhmanina","sequence":"additional","affiliation":[{"name":"Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","unstructured":"http:\/\/www.unaids.org\/sites\/ default\/files\/media_asset\/Global_AIDS_update_2017_en.pdf"},{"key":"ref=2","unstructured":"http:\/\/apps. who.int\/iris\/bitstream\/handle\/10665\/259517\/9789241513272-eng.pdf?sequence=1"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"e1002329","DOI":"10.1371\/journal.pmed.1002329","volume":"14","author":"Taylor M.","year":"2017","unstructured":"Taylor M, Newman L, Ishikawa N. Elimination of mother-to-child transmission of HIV and Syphilis (EMTCT): Process, progress, and program integration.","journal-title":"PLoS Med"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1097\/QAD.0000000000000212","volume":"28","author":"Townsend C.L.","year":"","unstructured":"Townsend CL, Byrne L, Cortina-Borja M. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000-2011.","journal-title":"Aids"},{"key":"ref=5","unstructured":"https:\/\/www.cdc.gov\/hiv\/library\/reports\/hiv-surveillance-archive.html#supplemental-archive"},{"key":"ref=6","unstructured":"http:\/\/www.unaids.org\/sites\/ default\/files\/media_asset\/unaids-data-2018_en.pdf"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/QAI.0000000000001616","volume":"77","author":"Knettel B.A.","year":"2018","unstructured":"Knettel BA, Cichowitz C, Ngocho JS. Retention in HIV Care During Pregnancy and the Postpartum Period in the Option B+ Era: Systematic Review and Meta-Analysis of Studies in Africa.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=8","unstructured":"https:\/\/www.unicef.org\/publications\/files\/Children_and_AIDS_Seventh_Stocktaking_Report_2016_EN.pdf.pdf"},{"key":"ref=9","unstructured":"http:\/\/ www.who.int\/hiv\/pub\/mtct\/en\/who_hiv_aids_2001.03.pdf?ua=1"},{"key":"ref=10","unstructured":"http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/75236\/9789241599818_eng.pdf?sequence=1"},{"key":"ref=11","unstructured":"http:\/\/www.who.int\/hiv\/pub\/guidelines\/arv2013\/en\/"},{"key":"ref=12","unstructured":"https:\/\/aidsreportingtool. unaids.org\/static\/docs\/GARPR_Guidelines_2016_EN.pdf"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10461-016-1670-9","volume":"21","author":"Idele P.","year":"2017","unstructured":"Idele P, Hayashi C, Porth T, Mamahit A, Mahy M. Prevention of Mother-to-Child Transmission of HIV and Paediatric HIV Care and Treatment Monitoring: From Measuring Process to Impact and Elimination of Mother-to-Child Transmission of HIV.","journal-title":"AIDS Behav"},{"key":"ref=14","unstructured":"http:\/\/www.who. int\/hiv\/pub\/arv\/policy-brief-arv-2015\/en\/"},{"key":"ref=15","unstructured":"http:\/\/apps. who.int\/iris\/bitstream\/handle\/10665\/208825\/9789241549684_eng.pdf?sequence=1"},{"key":"ref=16","unstructured":"http:\/\/www.eacsociety.org\/ files\/guidelines_9.0-english.pdf"},{"key":"ref=17","unstructured":""},{"key":"ref=18","unstructured":"http:\/\/apps.who.int\/ iris\/bitstream\/handle\/ 10665\/273129\/WHO-CDS-HIV-18.19-eng.pdf?ua=1"},{"key":"ref=19","unstructured":"http:\/\/www.eacsociety. org\/files\/2018_guidelines-9.1-english.pdf"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1086\/314431","volume":"178","author":"Moodley J.","year":"1998","unstructured":"Moodley J, Moodley D, Pillay K. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring.","journal-title":"J Infect Dis"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1111\/bcp.13310","volume":"83","author":"Marzolini C.","year":"2017","unstructured":"Marzolini C, Decosterd L, Winterfeld U. Free and total plasma concentrations of elvitegravir\/cobicistat during pregnancy and postpartum: A case report.","journal-title":"Br J Clin Pharmacol"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/QAD.0000000000000976","volume":"30","author":"Schalkwijk S.","year":"2016","unstructured":"Schalkwijk S, Colbers A, Konopnicki D, Greupink R, Russel FG, Burger D. network P. First reported use of elvitegravir and cobicistat during pregnancy.","journal-title":"AIDS"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s40262-014-0185-7","volume":"53","author":"McCormack S.A.","year":"2014","unstructured":"McCormack SA, Best BM. Protecting the fetus against HIV infection: A systematic review of placental transfer of antiretrovirals.","journal-title":"Clin Pharmacokinet"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3851\/IMP1918","volume":"16","author":"Else L.J.","year":"2011","unstructured":"Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).","journal-title":"Antivir Ther"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11095-018-2352-2","volume":"35","author":"Koren G.","year":"2018","unstructured":"Koren G, Pariente G. Pregnancy-associated changes in pharmacokinetics and their clinical implications.","journal-title":"Pharm Res"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"e1002160","DOI":"10.1371\/journal.pmed.1002160","volume":"13","author":"Pariente G.","year":"2016","unstructured":"Pariente G, Leibson T, Carls A, Adams-Webber T, Ito S, Koren G. Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review.","journal-title":"PLoS Med"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/hiv.12195","volume":"16","author":"Aweeka F.T.","year":"2015","unstructured":"Aweeka FT, Hu C, Huang L. Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics.","journal-title":"HIV Med"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/00498250701744633","volume":"38","author":"Jeong H.","year":"2008","unstructured":"Jeong H, Choi S, Song JW, Chen H, Fischer JH. Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination.","journal-title":"Xenobiotica"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1089\/08892220260190290","volume":"18","author":"Acosta E.P.","year":"2002","unstructured":"Acosta EP, Gerber JG. Position paper on therapeutic drug monitoring of antiretroviral agents.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/FTD.0b013e3181ddf717","volume":"32","author":"Burger D.M.","year":"2010","unstructured":"Burger DM. The role of therapeutic drug monitoring in pediatric HIV\/AIDS.","journal-title":"Ther Drug Monit"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/FTD.0b013e31821b42d1","volume":"33","author":"Pretorius E.","year":"2011","unstructured":"Pretorius E, Klinker H, Rosenkranz B. The role of therapeutic drug monitoring in the management of patients with human immunodeficiency virus infection.","journal-title":"Ther Drug Monit"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1080\/17512433.2016.1235972","volume":"9","author":"Punyawudho B.","year":"2016","unstructured":"Punyawudho B, Singkham N, Thammajaruk N. Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/phar.1626","volume":"35","author":"Gilbert E.M.","year":"2015","unstructured":"Gilbert EM, Darin KM, Scarsi KK, McLaughlin MM. Antiretroviral Pharmacokinetics in Pregnant Women.","journal-title":"Pharmacotherapy"},{"key":"ref=34","unstructured":"http:\/\/programme.aids2018.org\/Abstract\/Abstract\/5960"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1517\/14656566.2012.642865","volume":"13","author":"Akanbi M.O.","year":"2012","unstructured":"Akanbi MO, Scarsi KK, Taiwo B, Murphy RL. Combination nucleoside\/nucleotide reverse transcriptase inhibitors for treatment of HIV infection.","journal-title":"Expert Opin Pharmacother"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1468-1293.2011.00965.x","volume":"13","author":"Stek A.M.","year":"2012","unstructured":"Stek AM, Best BM, Luo W. Effect of pregnancy on emtricitabine pharmacokinetics.","journal-title":"HIV Med"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/QAD.0b013e32835c208b","volume":"27","author":"Colbers A.P.","year":"2013","unstructured":"Colbers AP, Hawkins DA, Gingelmaier A. network P. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women.","journal-title":"AIDS"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/01.aids.0000210609.52836.d1","volume":"20","author":"Best B.M.","year":"2006","unstructured":"Best BM, Mirochnick M, Capparelli EV. Impact of pregnancy on abacavir pharmacokinetics.","journal-title":"AIDS"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0140-6736(13)62187-X","volume":"383","author":"","year":"2014","unstructured":". Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): A randomised, double-blind, placebo-controlled, non-inferiority trial.","journal-title":"Lancet"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/COH.0000000000000385","volume":"12","author":"Boffito M.","year":"2017","unstructured":"Boffito M, Lamorde M, Watkins M, Pozniak A. Antiretroviral dose optimization: the future of efavirenz 400 mg dosing.","journal-title":"Curr Opin HIV AIDS"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/QAI.0b013e31823ff052","volume":"59","author":"Cressey T.R.","year":"2012","unstructured":"Cressey TR, Stek A, Capparelli E. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=42","unstructured":"http:\/\/www.croiconference.org\/sites\/default\/files\/posters-2016\/433.pdf"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/infdis\/jiu429","volume":"211","author":"Dooley K.E.","year":"2015","unstructured":"Dooley KE, Denti P, Martinson N. Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection.","journal-title":"J Infect Dis"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/cpt.43","volume":"97","author":"Olagunju A.","year":"2015","unstructured":"Olagunju A, Bolaji O, Amara A. Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics.","journal-title":"Clin Pharmacol Ther"},{"key":"ref=45","unstructured":"http:\/\/programme.ias2017.org\/Abstract\/Abstract\/5612"},{"key":"ref=46","unstructured":"https:\/\/www. ncbi.nlm.nih.gov\/pubmed\/29520730"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3389\/fphar.2016.00239","volume":"7","author":"Mulligan N.","year":"2016","unstructured":"Mulligan N, Schalkwijk S, Best BM. Etravirine Pharmacokinetics in HIV-Infected Pregnant Women.","journal-title":"Front Pharmacol"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/FPC.0000000000000227","volume":"26","author":"Olagunju A.","year":"2016","unstructured":"Olagunju A, Bolaji O, Neary M, Back D, Khoo S, Owen A. Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study.","journal-title":"Pharmacogenet Genomics"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/QAI.0000000000000968","volume":"72","author":"Tran A.H.","year":"2016","unstructured":"Tran AH, Best BM, Stek A. Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40121-017-0184-8","volume":"7","author":"Osiyemi O.","year":"2018","unstructured":"Osiyemi O, Yasin S, Zorrilla C. Pharmacokinetics, Antiviral Activity, and Safety of Rilpivirine in Pregnant Women with HIV-1 Infection: Results of a Phase 3b, Multicenter, Open-Label Study.","journal-title":"Infect Dis Ther"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1093\/cid\/cix534","volume":"65","author":"Schalkwijk S.","year":"2017","unstructured":"Schalkwijk S, Colbers A, Konopnicki D. Pharmacokinetics of newly developed antiretroviral agents in H. I. V. infected pregnant women Network. Lowered Rilpivirine Exposure During the Third Trimester of Pregnancy in Human Immunodeficiency Virus Type 1-Infected Women.","journal-title":"Clin Infect Dis"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/QAI.0000000000001068","volume":"73","author":"Ramgopal M.","year":"2016","unstructured":"Ramgopal M, Osiyemi O, Zorrilla C. Pharmacokinetics of Total and Unbound Etravirine in HIV-1-Infected Pregnant Women.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1468-1293.2008.00553.x","volume":"9","author":"Capparelli E.V.","year":"2008","unstructured":"Capparelli EV, Aweeka F, Hitti J. Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.","journal-title":"HIV Med"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/QAI.0b013e3181e9871b","volume":"55","author":"Lamorde M.","year":"2010","unstructured":"Lamorde M, Byakika-Kibwika P, Okaba-Kayom V. Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2165\/00003088-199732030-00003","volume":"32","author":"Barry M.","year":"1997","unstructured":"Barry M, Gibbons S, Back D, Mulcahy F. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.","journal-title":"Clin Pharmacokinet"},{"key":"ref=56","unstructured":"http:\/\/programme.aids2018.org\/Abstract\/ Abstract\/6026"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/jac\/dkx459","volume":"73","author":"Molto J.","year":"2018","unstructured":"Molto J, Curran A, Miranda C. Pharmacokinetics of darunavir\/cobicistat and etravirine alone and co-administered in HIV-infected patients.","journal-title":"J Antimicrob Chemother"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1089\/088922203769232629","volume":"19","author":"Boffito M.","year":"2003","unstructured":"Boffito M, Back DJ, Blaschke TF. Protein binding in antiretroviral therapies.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/QAI.0b013e318289b4d2","volume":"63","author":"Kreitchmann R.","year":"2013","unstructured":"Kreitchmann R, Best BM, Wang J. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/QAI.0b013e31820fd093","volume":"56","author":"Mirochnick M.","year":"2011","unstructured":"Mirochnick M, Best BM, Stek AM. Team IsS. Atazanavir pharmacokinetics with and without tenofovir during pregnancy.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1128\/AAC.48.6.2091-2096.2004","volume":"48","author":"Taburet A.M.","year":"2004","unstructured":"Taburet AM, Piketty C, Chazallon C. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3851\/IMP2936","volume":"20","author":"Le M.P.","year":"2015","unstructured":"Le MP, Mandelbrot L, Descamps D. Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300\/100 mg once daily) in HIV-1-infected pregnant women.","journal-title":"Antivir Ther"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3851\/IMP2820","volume":"20","author":"Colbers A.","year":"2015","unstructured":"Colbers A, Hawkins D, Hidalgo-Tenorio C. network P. Atazanavir exposure is effective during pregnancy regardless of tenofovir use.","journal-title":"Antivir Ther"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1097\/QAD.0b013e32825a69d1","volume":"21","author":"Ripamonti D.","year":"2007","unstructured":"Ripamonti D, Cattaneo D, Maggiolo F. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.","journal-title":"AIDS"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1093\/jac\/dkx274","volume":"72","author":"Foca E.","year":"2017","unstructured":"Foca E, Calcagno A, Bonito A. Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients.","journal-title":"J Antimicrob Chemother"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/jac\/dku400","volume":"70","author":"Colbers A.","year":"2015","unstructured":"Colbers A, Molto J, Ivanovic J. Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women.","journal-title":"J Antimicrob Chemother"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"19485","DOI":"10.7448\/IAS.17.4.19485","volume":"17","author":"Lambert J.","year":"2014","unstructured":"Lambert J, Jackson V, Else L. Darunavir pharmacokinetics throughout pregnancy and postpartum.","journal-title":"J Int AIDS Soc"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/hiv.12047","volume":"15","author":"Zorrilla C.D.","year":"2014","unstructured":"Zorrilla CD, Wright R, Osiyemi OO. Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir\/ritonavir 600\/100 mg administered twice daily.","journal-title":"HIV Med"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/hiv.12366","volume":"17","author":"Crauwels H.M.","year":"2016","unstructured":"Crauwels HM, Kakuda TN, Ryan B. Pharmacokinetics of once-daily darunavir\/ritonavir in HIV-1-infected pregnant women.","journal-title":"HIV Med"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/QAI.0000000000000668","volume":"70","author":"Stek A.","year":"2015","unstructured":"Stek A, Best BM, Wang J. Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=71","unstructured":"http:\/\/www.croiconference.org\/sites\/default\/files\/posters-2016\/775.pdf"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1128\/AAC.05186-11","volume":"56","author":"Else L.J.","year":"2012","unstructured":"Else LJ, Douglas M, Dickinson L, Back DJ, Khoo SH, Taylor GP. Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1468-1293.2010.00865.x","volume":"12","author":"Lambert J.S.","year":"2011","unstructured":"Lambert JS, Else LJ, Jackson V. Therapeutic drug monitoring of lopinavir\/ritonavir in pregnancy.","journal-title":"HIV Med"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1128\/AAC.02599-13","volume":"58","author":"Santini-Oliveira M.","year":"2014","unstructured":"Santini-Oliveira M, Estrela Rde C, Veloso VG. Randomized clinical trial comparing the pharmacokinetics of standard- and increased-dosage lopinavir-ritonavir coformulation tablets in HIV-positive pregnant women.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=75","unstructured":""},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1097\/01.aids.0000247114.43714.90","volume":"20","author":"Stek A.M.","year":"2006","unstructured":"Stek AM, Mirochnick M, Capparelli E. Reduced lopinavir exposure during pregnancy.","journal-title":"AIDS"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/QAI.0b013e318186edd0","volume":"49","author":"Mirochnick M.","year":"2008","unstructured":"Mirochnick M, Best BM, Stek AM. Team PsS. Lopinavir exposure with an increased dose during pregnancy.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/QAI.0b013e3181d6c9ed","volume":"54","author":"Best B.M.","year":"2010","unstructured":"Best BM, Stek AM, Mirochnick M. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3851\/IMP2328","volume":"18","author":"Fayet-Mello A.","year":"2013","unstructured":"Fayet-Mello A, Buclin T, Guignard N. Swiss HIVCS, Mother, Child HIVCS. Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women.","journal-title":"Antivir Ther"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/QAI.0b013e31827fd47e","volume":"63","author":"Patterson K.B.","year":"2013","unstructured":"Patterson KB, Dumond JB, Prince HA. Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/QAD.0000000000001755","volume":"32","author":"Mulligan N.","year":"2018","unstructured":"Mulligan N, Best BM, Wang J. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.","journal-title":"AIDS"},{"key":"ref=82","unstructured":"http:\/\/www.natap.org\/ 2017\/Pharm\/Pharm_34.htm"},{"key":"ref=83","unstructured":"http:\/\/programme.aids2018.org\/Abstract\/Abstract\/13144"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/cid\/civ366","volume":"61","author":"Blonk M.I.","year":"2015","unstructured":"Blonk MI, Colbers AP, Hidalgo-Tenorio C. Pharmacokinetics of Newly Developed Antiretroviral Agents in HIVIPWPN, Network P. Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy.","journal-title":"Clin Infect Dis"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/QAI.0000000000000318","volume":"67","author":"Watts D.H.","year":"2014","unstructured":"Watts DH, Stek A, Best BM. team Iss. Raltegravir pharmacokinetics during pregnancy.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=86","unstructured":""},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1097\/QAD.0000000000001992","volume":"32","author":"Momper J.D.","year":"2018","unstructured":"Momper JD, Best BM, Wang J. Elvitegravir\/cobicistat pharmacokinetics in pregnant and postpartum women with HIV.","journal-title":"AIDS"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/cid\/civ587","volume":"61","author":"Colbers A.","year":"2015","unstructured":"Colbers A, Best B, Schalkwijk S. the IST. Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women.","journal-title":"Clin Infect Dis"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1097\/QAD.0000000000001046","volume":"30","author":"Schalkwijk S.","year":"2016","unstructured":"Schalkwijk S, Colbers A, Konopnicki D. network P. The pharmacokinetics of abacavir 600 mg once daily in HIV-1-positive pregnant women.","journal-title":"AIDS"},{"key":"ref=90","unstructured":"http:\/\/www.natap.org\/2018\/CROI\/HIV"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/jcp.2008.055277","volume":"61","author":"Huppertz B.","year":"2008","unstructured":"Huppertz B. The anatomy of the normal placenta.","journal-title":"J Clin Pathol"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1056\/NEJM199411033311801","volume":"331","author":"Connor E.M.","year":"1994","unstructured":"Connor EM, Sperling RS, Gelber R. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.","journal-title":"N Engl J Med"},{"key":"ref=93","unstructured":"http:\/\/www.who.int\/hiv\/ pub\/mtct\/arv_guidelines_mtct.pdf?ua=1"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.clpt.2005.05.002","volume":"78","author":"Marzolini C.","year":"2005","unstructured":"Marzolini C, Kim RB. Placental transfer of antiretroviral drugs.","journal-title":"Clin Pharmacol Ther"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-9440(10)62230-4","volume":"166","author":"Meyer Zu Schwabedissen H.E.","year":"2005","unstructured":"Meyer Zu Schwabedissen HE, Grube M, Heydrich B. Expression, localization, and function of MRP5 (ABCC5), a transporter for cyclic nucleotides, in human placenta and cultured human trophoblasts: effects of gestational age and cellular differentiation.","journal-title":"Am J Pathol"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1053\/plac.2002.0907","volume":"24","author":"Sato K.","year":"2003","unstructured":"Sato K, Sugawara J, Sato T. Expression of organic anion transporting polypeptide E (OATP-E) in human placenta.","journal-title":"Placenta"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"E390","DOI":"10.1152\/ajpendo.00257.2002","volume":"284","author":"Ugele B.","year":"2003","unstructured":"Ugele B, St-Pierre MV, Pihusch M, Bahn A, Hantschmann P. Characterization and identification of steroid sulfate transporters of human placenta.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1124\/jpet.105.086827","volume":"315","author":"Sata R.","year":"2005","unstructured":"Sata R, Ohtani H, Tsujimoto M. Functional analysis of organic cation transporter 3 expressed in human placenta.","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"R1809","DOI":"10.1152\/ajpregu.00293.2007","volume":"293","author":"Govindarajan R.","year":"2007","unstructured":"Govindarajan R, Bakken AH, Hudkins KL. In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3109\/1061186X.2012.716847","volume":"20","author":"Staud F.","year":"2012","unstructured":"Staud F, Cerveny L, Ceckova M. Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure.","journal-title":"J Drug Target"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11095-017-2286-0","volume":"35","author":"Tetro N.","year":"2018","unstructured":"Tetro N, Moushaev S, Rubinchik-Stern M, Eyal S. The Placental Barrier: the Gate and the Fate in Drug Distribution.","journal-title":"Pharm Res"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0890-6238(98)00027-6","volume":"12","author":"Lankas G.R.","year":"1998","unstructured":"Lankas GR, Wise LD, Cartwright ME, Pippert T, Umbenhauer DR. Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice.","journal-title":"Reprod Toxicol"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"R963","DOI":"10.1152\/ajpregu.00173.2005","volume":"289","author":"Mathias A.A.","year":"2005","unstructured":"Mathias AA, Hitti J, Unadkat JD. P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clpt.2003.09.012","volume":"75","author":"Marzolini C.","year":"2004","unstructured":"Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance.","journal-title":"Clin Pharmacol Ther"},{"key":"ref=105","unstructured":""},{"key":"ref=106","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s40262-018-0684-z","volume":"58","author":"van der Galien R.","year":"2019","unstructured":"van der Galien R, Ter Heine R, Greupink R. Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps.","journal-title":"Clin Pharmacokinet"},{"key":"ref=107","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1021\/mp300712a","volume":"10","author":"Marzolini C.","year":"2013","unstructured":"Marzolini C, Mueller R, Li-Blatter X, Battegay M, Seelig A. The brain entry of HIV-1 protease inhibitors is facilitated when used in combination.","journal-title":"Mol Pharm"},{"key":"ref=108","unstructured":"https:\/\/chemicalize.com\/"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1128\/AAC.48.11.4332-4336.2004","volume":"48","author":"Chappuy H.","year":"2004","unstructured":"Chappuy H, Treluyer JM, Jullien V. Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=110","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1128\/AAC.03469-14","volume":"58","author":"Fauchet F.","year":"2014","unstructured":"Fauchet F, Treluyer JM, Preta LH. Population pharmacokinetics of abacavir in pregnant women.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=111","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1128\/AAC.00860-08","volume":"53","author":"Hirt D.","year":"2009","unstructured":"Hirt D, Urien S, Rey E. Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=112","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.1128\/AAC.00544-11","volume":"55","author":"Flynn P.M.","year":"2011","unstructured":"Flynn PM, Mirochnick M, Shapiro DE. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=113","doi-asserted-by":"crossref","first-page":"e02213","DOI":"10.1128\/AAC.02213-16","volume":"61","author":"Rimawi B.H.","year":"2017","unstructured":"Rimawi BH, Johnson E, Rajakumar A. Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1093\/jac\/dkt095","volume":"68","author":"Calcagno A.","year":"2013","unstructured":"Calcagno A, Trentini L, Marinaro L. Transplacental passage of etravirine and maraviroc in a multidrug-experienced HIV-infected woman failing on darunavir-based HAART in late pregnancy.","journal-title":"J Antimicrob Chemother"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1128\/AAC.01523-08","volume":"53","author":"Yeh R.F.","year":"2009","unstructured":"Yeh RF, Rezk NL, Kashuba AD. Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1067\/mob.2001.108344","volume":"184","author":"Mandelbrot L.","year":"2001","unstructured":"Mandelbrot L, Peytavin G, Firtion G, Farinotti R. Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women.","journal-title":"Am J Obstet Gynecol"},{"key":"ref=117","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1128\/AAC.00370-11","volume":"56","author":"Benaboud S.","year":"2012","unstructured":"Benaboud S, Treluyer JM, Urien S. Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=118","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/QAI.0b013e3182a921eb","volume":"65","author":"Mirochnick M.","year":"2014","unstructured":"Mirochnick M, Taha T, Kreitchmann R. Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/clpt.2008.201","volume":"85","author":"Hirt D.","year":"2009","unstructured":"Hirt D, Urien S, Ekouevi DK. Anrs. Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109).","journal-title":"Clin Pharmacol Ther"},{"key":"ref=120","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1468-1293.2007.00495.x","volume":"8","author":"Mirochnick M.","year":"2007","unstructured":"Mirochnick M, Rodman JH, Robbins BL. Pharmacokinetics of oral zidovudine administered during labour: A preliminary study.","journal-title":"HIV Med"},{"key":"ref=121","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1086\/315152","volume":"180","author":"Rodman J.H.","year":"1999","unstructured":"Rodman JH, Flynn PM, Robbins B. Systemic pharmacokinetics and cellular pharmacology of zidovudine in human immunodeficiency virus type 1-infected women and newborn infants.","journal-title":"J Infect Dis"},{"key":"ref=122","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/infdis\/163.2.226","volume":"163","author":"Watts D.H.","year":"1991","unstructured":"Watts DH, Brown ZA, Tartaglione T. Pharmacokinetic disposition of zidovudine during pregnancy.","journal-title":"J Infect Dis"},{"key":"ref=123","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bcp.12459","volume":"78","author":"Fauchet F.","year":"2014","unstructured":"Fauchet F, Treluyer JM, Valade E. Maternal and fetal zidovudine pharmacokinetics during pregnancy and labour: too high dose infused at labour?","journal-title":"Br J Clin Pharmacol"},{"key":"ref=124","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1479-828X.1998.tb03068.x","volume":"38","author":"Phuapradit W.","year":"1998","unstructured":"Phuapradit W, Sirinavin S, Taneepanichskul S. Maternal and umbilical cord serum zidovudine levels in human immunodeficiency virus infection.","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"ref=125","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1468-1293.2010.00874.x","volume":"12","author":"Izurieta P.","year":"2011","unstructured":"Izurieta P, Kakuda TN, Feys C, Witek J. Safety and pharmacokinetics of etravirine in pregnant HIV-1-infected women.","journal-title":"HIV Med"},{"key":"ref=126","doi-asserted-by":"crossref","first-page":"620","DOI":"10.2174\/157016209789973628","volume":"7","author":"Ivanovic J.","year":"2009","unstructured":"Ivanovic J, Nicastri E, Anceschi MM. Pregnancy, Newborn Clinical Outcome Group in HIVI. Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women.","journal-title":"Curr HIV Res"},{"key":"ref=127","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1128\/AAC.00631-10","volume":"55","author":"Benaboud S.","year":"2011","unstructured":"Benaboud S, Ekouevi DK, Urien S. Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=128","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/S0140-6736(00)02383-7","volume":"355","author":"Taylor G.P.","year":"2000","unstructured":"Taylor GP, Lyall EG, Back D, Ward C, Tudor-Williams G. Pharmacological implications of lengthened in-utero exposure to nevirapine.","journal-title":"Lancet"},{"key":"ref=129","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/00002030-199903110-00006","volume":"13","author":"Musoke P.","year":"1999","unstructured":"Musoke P, Guay LA, Bagenda D. A phase I\/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006).","journal-title":"AIDS"},{"key":"ref=130","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/00002030-200204120-00008","volume":"16","author":"Marzolini C.","year":"2002","unstructured":"Marzolini C, Rudin C, Decosterd LA. Swiss Mother + Child HIVCS. Transplacental passage of protease inhibitors at delivery.","journal-title":"AIDS"},{"key":"ref=131","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1086\/515641","volume":"178","author":"Mirochnick M.","year":"1998","unstructured":"Mirochnick M, Fenton T, Gagnier P. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team.","journal-title":"J Infect Dis"},{"key":"ref=132","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1097\/01.aids.0000242820.67001.2c","volume":"20","author":"Gingelmaier A.","year":"2006","unstructured":"Gingelmaier A, Kurowski M, Kastner R. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery.","journal-title":"AIDS"},{"key":"ref=133","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1468-1293.2011.00927.x","volume":"12","author":"Conradie F.","year":"2011","unstructured":"Conradie F, Zorrilla C, Josipovic D. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.","journal-title":"HIV Med"},{"key":"ref=134","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/01.aids.0000202653.49020.dd","volume":"20","author":"Lechelt M.","year":"2006","unstructured":"Lechelt M, Lyons F, Clarke A, Magaya V, Issa R, de Ruiter A. Human placental transfer of atazanavir: A case report.","journal-title":"AIDS"},{"key":"ref=135","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/QAD.0b013e32833653b2","volume":"24","author":"Ivanovic J.","year":"2010","unstructured":"Ivanovic J, Bellagamba R, Nicastri E. Use of darunavir\/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety.","journal-title":"AIDS"},{"key":"ref=136","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1258\/ijsa.2008.008515","volume":"20","author":"Ripamonti D.","year":"2009","unstructured":"Ripamonti D, Cattaneo D, Cortinovis M, Maggiolo F, Suter F. Transplacental passage of ritonavir-boosted darunavir in two pregnant women.","journal-title":"Int J STD AIDS"},{"key":"ref=137","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3851\/IMP1473","volume":"15","author":"Pinnetti C.","year":"2010","unstructured":"Pinnetti C, Tamburrini E, Ragazzoni E, De Luca A, Navarra P. Decreased plasma levels of darunavir\/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1.","journal-title":"Antivir Ther"},{"key":"ref=138","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1093\/jac\/dkq264","volume":"65","author":"Pinnetti C.","year":"2010","unstructured":"Pinnetti C, Baroncelli S, Villani P. Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy.","journal-title":"J Antimicrob Chemother"},{"key":"ref=139","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s00228-012-1250-5","volume":"68","author":"Croci L.","year":"2012","unstructured":"Croci L, Trezzi M, Allegri MP. Pharmacokinetic and safety of raltegravir in pregnancy.","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=140","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1097\/QAD.0000000000001055","volume":"30","author":"Lewis J.M.","year":"2016","unstructured":"Lewis JM, Railton E, Riordan A, Khoo S, Chaponda M. Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing.","journal-title":"AIDS"},{"key":"ref=141","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3851\/IMP2474","volume":"18","author":"Shapiro R.L.","year":"2013","unstructured":"Shapiro RL, Rossi S, Ogwu A. Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana.","journal-title":"Antivir Ther"},{"key":"ref=142","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/jac\/dkx507","volume":"73","author":"Waitt C.","year":"2018","unstructured":"Waitt C, Olagunju A, Nakalema S. Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs.","journal-title":"J Antimicrob Chemother"},{"key":"ref=143","doi-asserted-by":"crossref","first-page":"e1002132","DOI":"10.1371\/journal.pmed.1002132","volume":"13","author":"Mugwanya K.K.","year":"2016","unstructured":"Mugwanya KK, Hendrix CW, Mugo NR. Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption.","journal-title":"PLoS Med"},{"key":"ref=144","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3851\/IMP2739","volume":"19","author":"Corbett A.H.","year":"2014","unstructured":"Corbett AH, Kayira D, White NR. Antiretroviral pharmacokinetics in mothers and breastfeeding infants from 6 to 24 weeks post-partum: results of the BAN Study.","journal-title":"Antivir Ther"},{"key":"ref=145","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/QAI.0b013e31802c5441","volume":"44","author":"Giuliano M.","year":"2007","unstructured":"Giuliano M, Guidotti G, Andreotti M. Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load: A study within the Drug Resource Enhancement Against AIDS and Malnutrition Program.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=146","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3851\/IMP2315","volume":"17","author":"Palombi L.","year":"2012","unstructured":"Palombi L, Pirillo MF, Andreotti M. Antiretroviral prophylaxis for breastfeeding transmission in Malawi: drug concentrations, virological efficacy and safety.","journal-title":"Antivir Ther"},{"key":"ref=147","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1093\/jac\/dkv435","volume":"71","author":"Palombi L.","year":"2016","unstructured":"Palombi L, Pirillo MF, Marchei E. Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi.","journal-title":"J Antimicrob Chemother"},{"key":"ref=148","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1128\/AAC.01117-08","volume":"53","author":"Mirochnick M.","year":"2009","unstructured":"Mirochnick M, Thomas T, Capparelli E. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=149","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1086\/432483","volume":"192","author":"Shapiro R.L.","year":"2005","unstructured":"Shapiro RL, Holland DT, Capparelli E. Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment.","journal-title":"J Infect Dis"},{"key":"ref=150","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/QAI.0b013e31817bbc21","volume":"48","author":"Schneider S.","year":"2008","unstructured":"Schneider S, Peltier A, Gras A. Efavirenz in human breast milk, mothers\u2019, and newborns\u2019 plasma.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=151","unstructured":"http:\/\/www.croiconference.org\/ sites\/default\/files\/posters\/891.pdf"},{"key":"ref=152","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1097\/01.aids.0000188428.33280.41","volume":"19","author":"Colebunders R.","year":"2005","unstructured":"Colebunders R, Hodossy B, Burger D. The effect of highly active antiretroviral treatment on viral load and antiretroviral drug levels in breast milk.","journal-title":"AIDS"},{"key":"ref=153","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1097\/QAD.0000000000001259","volume":"30","author":"Kobbe R.","year":"2016","unstructured":"Kobbe R, Schalkwijk S, Dunay G. Dolutegravir in breast milk and maternal and infant plasma during breastfeeding.","journal-title":"AIDS"},{"key":"ref=154","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/00498250903509375","volume":"40","author":"Annaert P.","year":"2010","unstructured":"Annaert P, Ye ZW, Stieger B, Augustijns P. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1.","journal-title":"Xenobiotica"},{"key":"ref=155","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/QAI.0000000000001699","volume":"78","author":"Begley R.","year":"2018","unstructured":"Begley R, Das M, Zhong L, Ling J, Kearney BP, Custodio JM. Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=156","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1177\/135965350400900617","volume":"9","author":"Cano-Soldado P.","year":"2004","unstructured":"Cano-Soldado P, Lorrayoz IM, Molina-Arcas M. Interaction of nucleoside inhibitors of HIV-1 reverse transcriptase with the concentrative nucleoside transporter-1 (SLC28A1).","journal-title":"Antivir Ther"},{"key":"ref=157","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.1128\/AAC.00648-16","volume":"60","author":"Ceckova M.","year":"2016","unstructured":"Ceckova M, Reznicek J, Ptackova Z. Role of ABC and Solute Carrier Transporters in the Placental Transport of Lamivudine.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=158","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1081\/NCN-100002341","volume":"20","author":"Cihlar T.","year":"2001","unstructured":"Cihlar T, Ho ES, Lin DC, Mulato AS. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"ref=159","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/jcph.256","volume":"54","author":"Custodio J.M.","year":"2014","unstructured":"Custodio JM, Wang H, Hao J. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.","journal-title":"J Clin Pharmacol"},{"key":"ref=160","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1128\/AAC.04594-14","volume":"59","author":"Hoque M.T.","year":"2015","unstructured":"Hoque MT, Kis O, De Rosa MF, Bendayan R. Raltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=161","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2125.2008.03198.x","volume":"66","author":"Hyland R.","year":"2008","unstructured":"Hyland R, Dickins M, Collins C, Jones H, Jones B. Maraviroc: assessment of drug-drug interaction potential.","journal-title":"Br J Clin Pharmacol"},{"key":"ref=162","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1124\/jpet.110.166314","volume":"334","author":"Kis O.","year":"2010","unstructured":"Kis O, Zastre JA, Ramaswamy M, Bendayan R. pH dependence of organic anion-transporting polypeptide 2B1 in Caco-2 cells: potential role in antiretroviral drug oral bioavailability and drug-drug interactions.","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=163","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/ki.2014.66","volume":"86","author":"Lepist E.I.","year":"2014","unstructured":"Lepist EI, Zhang X, Hao J. Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat.","journal-title":"Kidney Int"},{"key":"ref=164","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1128\/AAC.06407-11","volume":"56","author":"Moss D.M.","year":"2012","unstructured":"Moss DM, Siccardi M, Murphy M. Divalent metals and pH alter raltegravir disposition","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=165","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.bcp.2013.07.008","volume":"86","author":"Muller F.","year":"2013","unstructured":"Muller F, Konig J, Hoier E, Mandery K, Fromm MF. Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine.","journal-title":"Biochem Pharmacol"},{"key":"ref=166","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1124\/dmd.112.048918","volume":"41","author":"Reese M.J.","year":"2013","unstructured":"Reese MJ, Savina PM, Generaux GT. investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.","journal-title":"Drug Metab Dispos"},{"key":"ref=167","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/00498254.2016.1158886","volume":"47","author":"Reznicek J.","year":"2017","unstructured":"Reznicek J, Ceckova M, Cerveny L, Muller F, Staud F. Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters.","journal-title":"Xenobiotica"},{"key":"ref=168","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1124\/dmd.107.017723","volume":"35","author":"Shaik N.","year":"2007","unstructured":"Shaik N, Giri N, Pan G, Elmquist WF. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution.","journal-title":"Drug Metab Dispos"},{"key":"ref=169","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1124\/jpet.300.3.918","volume":"300","author":"Takeda M.","year":"2002","unstructured":"Takeda M, Khamdang S, Narikawa S. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport.","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=170","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1124\/mol.63.1.65","volume":"63","author":"Wang X.","year":"2003","unstructured":"Wang X, Furukawa T, Nitanda T. Breast cancer resistance protein (BCRP\/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors.","journal-title":"Mol Pharmacol"},{"key":"ref=171","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/jac\/dkl474","volume":"59","author":"Weiss J.","year":"2007","unstructured":"Weiss J, Rose J, Storch CH. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs.","journal-title":"J Antimicrob Chemother"},{"key":"ref=172","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1124\/dmd.106.012765","volume":"35","author":"Weiss J.","year":"2007","unstructured":"Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, Haefeli WE. Inhibition of MRP1\/ABCC1, MRP2\/ABCC2, and MRP3\/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.","journal-title":"Drug Metab Dispos"},{"key":"ref=173","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/09687680110048318","volume":"18","author":"Yao S.Y.","year":"2001","unstructured":"Yao SY, Ng AM, Sundaram M, Cass CE, Baldwin SA, Young JD. Transport of antiviral 3\u2032-deoxy-nucleoside drugs by recombinant human and rat equilibrative, nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins produced in Xenopus oocytes.","journal-title":"Mol Membr Biol"},{"key":"ref=174","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/bdd.701","volume":"31","author":"Ye Z.W.","year":"2010","unstructured":"Ye ZW, Camus S, Augustijns P, Annaert P. Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes.","journal-title":"Biopharm Drug Dispos"},{"key":"ref=175","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1128\/AAC.01527-10","volume":"55","author":"Zembruski N.C.","year":"2011","unstructured":"Zembruski NC, Haefeli WE, Weiss J. Interaction potential of etravirine with drug transporters assessed","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=176","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.1016\/S2352-3018(18)30059-6","volume":"5","author":"Bailey H.","year":"2018","unstructured":"Bailey H, Zash R, Rasi V, Thorne C. HIV treatment in pregnancy.","journal-title":"Lancet HIV"},{"key":"ref=177","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/cid\/cis198","volume":"54","author":"Sibiude J.","year":"2012","unstructured":"Sibiude J, Warszawski J, Tubiana R. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost?","journal-title":"Clin Infect Dis"},{"key":"ref=178","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/infdis\/jir307","volume":"204","author":"Powis K.M.","year":"2011","unstructured":"Powis KM, Kitch D, Ogwu A. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy.","journal-title":"J Infect Dis"},{"key":"ref=179","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1086\/507045","volume":"195","author":"Ravizza M.","year":"2007","unstructured":"Ravizza M, Martinelli P, Bucceri A. Italian Group on Surveillance on Antiretroviral Treatment in P. Treatment with protease inhibitors and coinfection with hepatitis C virus are independent predictors of preterm delivery in HIV-infected pregnant women.","journal-title":"J Infect Dis"},{"key":"ref=180","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1086\/511983","volume":"195","author":"Fiore S.","year":"2007","unstructured":"Fiore S, Ferrazzi E, Newell ML, Trabattoni D, Clerici M. Protease inhibitor-associated increased risk of preterm delivery is an immunological complication of therapy.","journal-title":"J Infect Dis"},{"key":"ref=181","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1511691","volume":"375","author":"Fowler M.G.","year":"2016","unstructured":"Fowler MG, Qin M, Fiscus SA. Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention.","journal-title":"N Engl J Med"},{"key":"ref=182","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/cid\/ciw159","volume":"62","author":"Jao J.","year":"2016","unstructured":"Jao J, Abrams EJ, Phillips T, Petro G, Zerbe A, Myer L. tenofovir exposure is not associated with fetal long bone growth.","journal-title":"Clin Infect Dis"},{"key":"ref=183","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/cid\/civ437","volume":"61","author":"Siberry G.K.","year":"2015","unstructured":"Siberry GK, Jacobson DL, Kalkwarf HJ. Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy.","journal-title":"Clin Infect Dis"},{"key":"ref=184","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3851\/IMP1909","volume":"16","author":"Vigano A.","year":"2011","unstructured":"Vigano A, Mora S, Giacomet V. In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers.","journal-title":"Antivir Ther"},{"key":"ref=185","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1097\/QAD.0000000000001156","volume":"30","author":"Denneman L.","year":"2016","unstructured":"Denneman L, Cohen S, Godfried MH. In-utero exposure to tenofovir is associated with impaired fetal and infant growth: need for follow-up studies in combination antiretroviral therapy\/HIV-exposed infants.","journal-title":"AIDS"},{"key":"ref=186","first-page":"525","volume":"30","author":"Liotta G.","year":"2016","unstructured":"Liotta G, Floridia M, Andreotti M. Growth indices in breastfed infants pre and postnatally exposed to tenofovir compared with tenofovir-unexposed infants.","journal-title":"AIDS"},{"key":"ref=187","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/QAI.0b013e3182a7adb2","volume":"64","author":"Ransom C.E.","year":"2013","unstructured":"Ransom CE, Huo Y, Patel K. Group PTotIMPAACT. Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=188","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/QAD.0000000000000916","volume":"30","author":"Williams P.L.","year":"2016","unstructured":"Williams PL, Hazra R, Van Dyke RB. Antiretroviral exposure during pregnancy and adverse outcomes in HIV-exposed uninfected infants and children using a trigger-based design.","journal-title":"AIDS"},{"key":"ref=189","author":"Kourtis A.P.","year":"2018","unstructured":"Kourtis AP, Wiener J, Wang L. Tenofovir disoproxil fumarate use during pregnancy and infant bone health: the Tenofovir in Pregnancy Pilot Study.","journal-title":"Pediatr Infect Dis J"},{"key":"ref=190","unstructured":"https:\/\/www.accessdata.fda.gov\/ drugsatfda_docs\/label\/2005\/020972s026,021360s013lbl.pdf"},{"key":"ref=191","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1097\/QAD.0000000000000231","volume":"28","author":"Ford N.","year":"2014","unstructured":"Ford N, Mofenson L, Shubber Z. Safety of efavirenz in the first trimester of pregnancy: An updated systematic review and meta-analysis.","journal-title":"AIDS"},{"key":"ref=192","doi-asserted-by":"crossref","first-page":"e172222","DOI":"10.1001\/jamapediatrics.2017.2222","volume":"171","author":"Zash R.","year":"2017","unstructured":"Zash R, Jacobson DL, Diseko M. Comparative Safety of Antiretroviral Treatment Regimens in Pregnancy.","journal-title":"JAMA Pediatr"},{"key":"ref=193","unstructured":"http:\/\/www.apregistry.com\/"},{"key":"ref=194","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1056\/NEJMc1807653","volume":"379","author":"Zash R.","year":"2018","unstructured":"Zash R, Makhema J, Shapiro RL. Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception.","journal-title":"N Engl J Med"},{"key":"ref=195","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/occmed\/51.4.230","volume":"51","author":"Shi L.","year":"2001","unstructured":"Shi L, Chia SE. A review of studies on maternal occupational exposures and birth defects, and the limitations associated with these studies.","journal-title":"Occup Med (Lond)"},{"key":"ref=196","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/INF.0000000000000926","volume":"35","author":"Hofer C.B.","year":"2016","unstructured":"Hofer CB, Keiser O, Zwahlen M. In Utero Exposure to Antiretroviral Drugs: Effect on Birth Weight and Growth Among HIV-exposed Uninfected Children in Brazil.","journal-title":"Pediatr Infect Dis J"},{"key":"ref=197","doi-asserted-by":"crossref","first-page":"e11762","DOI":"10.1371\/journal.pone.0011762","volume":"5","author":"Suchard M.S.","year":"2010","unstructured":"Suchard MS, Mayne E, Green VA. FOXP3 expression is upregulated in CD4T cells in progressive HIV-1 infection and is a marker of disease severity.","journal-title":"PLoS One"},{"key":"ref=198","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMp1809688","volume":"379","author":"Rasmussen S.A.","year":"2018","unstructured":"Rasmussen SA, Barfield W, Honein MA. Protecting Mothers and Babies - A Delicate Balancing Act.","journal-title":"N Engl J Med"},{"key":"ref=199","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1471-0528.1998.tb10227.x","volume":"105","author":"Brocklehurst P.","year":"1998","unstructured":"Brocklehurst P, French R. The association between maternal HIV infection and perinatal outcome: A systematic review of the literature and meta-analysis.","journal-title":"Br J Obstet Gynaecol"},{"key":"ref=200","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/S2352-3018(15)00207-6","volume":"3","author":"Wedi C.O.","year":"2016","unstructured":"Wedi CO, Kirtley S, Hopewell S, Corrigan R, Kennedy SH, Hemelaar J. Perinatal outcomes associated with maternal HIV infection: A systematic review and meta-analysis.","journal-title":"Lancet HIV"},{"key":"ref=201","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S0169-409X(03)00031-0","volume":"55","author":"Ito S.","year":"2003","unstructured":"Ito S, Alcorn J. Xenobiotic transporter expression and function in the human mammary gland.","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=202","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1124\/jpet.102.038315","volume":"303","author":"Alcorn J.","year":"2002","unstructured":"Alcorn J, Lu X, Moscow JA, McNamara PJ. Transporter gene expression in lactating and nonlactating human mammary epithelial cells using real-time reverse transcription-polymerase chain reaction.","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=203","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nm1186","volume":"11","author":"Jonker J.W.","year":"2005","unstructured":"Jonker JW, Merino G, Musters S. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk.","journal-title":"Nat Med"},{"key":"ref=204","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.addr.2008.08.007","volume":"61","author":"Vlaming M.L.","year":"2009","unstructured":"Vlaming ML, Lagas JS, Schinkel AH. Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice.","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=205","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1472-8206.2009.00760.x","volume":"24","author":"Gilchrist S.E.","year":"2010","unstructured":"Gilchrist SE, Alcorn J. Lactation stage-dependent expression of transporters in rat whole mammary gland and primary mammary epithelial organoids.","journal-title":"Fundam Clin Pharmacol"},{"key":"ref=206","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1023\/B:PHAM.0000022401.14710.c5","volume":"21","author":"McNamara P.J.","year":"2004","unstructured":"McNamara PJ, Abbassi M. Neonatal exposure to drugs in breast milk.","journal-title":"Pharm Res"},{"key":"ref=207","unstructured":"https:\/\/www.fda.gov\/downloads\/ regulatoryinformation\/guidances\/ucm127505.pdf"},{"key":"ref=208","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/cid\/civ317","volume":"61","author":"Olagunju A.","year":"2015","unstructured":"Olagunju A, Bolaji O, Amara A. Breast milk pharmacokinetics of efavirenz and breastfed infants\u2019 exposure in genetically defined subgroups of mother-infant pairs: An observational study.","journal-title":"Clin Infect Dis"},{"key":"ref=209","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/089033402237904","volume":"18","author":"Begg E.J.","year":"2002","unstructured":"Begg EJ, Duffull SB, Hackett LP, Ilett KF. Studying drugs in human milk: time to unify the approach.","journal-title":"J Hum Lact"},{"key":"ref=210","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/jac\/dkv080","volume":"70","author":"Waitt C.J.","year":"2015","unstructured":"Waitt CJ, Garner P, Bonnett LJ, Khoo SH, Else LJ. Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies.","journal-title":"J Antimicrob Chemother"},{"key":"ref=211","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJM200007133430208","volume":"343","author":"Ito S.","year":"2000","unstructured":"Ito S. Drug therapy for breast-feeding women.","journal-title":"N Engl J Med"},{"key":"ref=212","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/cid\/cir008","volume":"52","author":"Fogel J.","year":"2011","unstructured":"Fogel J, Li Q, Taha TE. Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants.","journal-title":"Clin Infect Dis"},{"key":"ref=213","unstructured":"https:\/\/www.fda.gov\/downloads\/ Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ UCM603873.pdf"},{"key":"ref=214","unstructured":"http:\/\/regist2.virology-education.com\/ 2016\/17HIVHEPPK\/04_Colbers.pdf"},{"key":"ref=215","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/bcp.12685","volume":"80","author":"De Sousa Mendes M.","year":"2015","unstructured":"De Sousa Mendes M, Hirt D, Urien S. Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women.","journal-title":"Br J Clin Pharmacol"},{"key":"ref=216","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s40262-015-0325-8","volume":"55","author":"Colbers A.","year":"2016","unstructured":"Colbers A, Greupink R, Litjens C, Burger D, Russel FG. Physiologically based modelling of darunavir\/ritonavir pharmacokinetics during pregnancy.","journal-title":"Clin Pharmacokinet"},{"key":"ref=217","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s40262-017-0583-8","volume":"57","author":"Schalkwijk S.","year":"2018","unstructured":"Schalkwijk S, Buaben AO, Freriksen JJM. Prediction of fetal darunavir exposure by integrating human ex-vivo placental transfer and physiologically based pharmacokinetic modeling.","journal-title":"Clin Pharmacokinet"},{"key":"ref=218","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3138\/ijfab.1.2.5","volume":"1","author":"Lyerly A.D.","year":"2008","unstructured":"Lyerly AD, Little MO, Faden R. The second wave: Toward responsible inclusion of pregnant women in research.","journal-title":"Int J Fem Approaches Bioeth"},{"key":"ref=219","doi-asserted-by":"crossref","first-page":"S437","DOI":"10.1093\/cid\/ciu709","volume":"59","author":"Sheffield J.S.","year":"2014","unstructured":"Sheffield JS, Siegel D, Mirochnick M. Designing drug trials: considerations for pregnant women.","journal-title":"Clin Infect Dis"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/170886","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T23:45:21Z","timestamp":1721087121000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/170886\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,3]]},"references-count":219,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,6,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612825666190320162507","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-02-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}